NANOBIOTIX ANNOUNCES FIRST EVER RADIOENHANCER TO RECEIVE EUROPEAN MARKET APPROVAL

Apr 04, 2019

Posted by Nanobiotix

Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer

Apr 03, 2019

Posted by Nanobiotix

Charles River Laboratories Highlights Commitment to Oncology Research at 2019 AACR Annual Meeting

Apr 02, 2019

Posted by Charles River Laboratories

iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer

Apr 02, 2019

AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PDTM Conference

Mar 29, 2019

5TH Annual Science of Stability Conference Announces Location and Themes

Mar 29, 2019

Posted by FreeThink Technologies, Inc.

Learn To Ask The Right Questions About Your Equity Awards

Mar 28, 2019

Posted by Freedom Trail Financial

Accelerated Stability Workshop & Training

Mar 26, 2019

Posted by FreeThink Technologies, Inc.